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Abstract
Background: The virulence, antimicrobial resistance, and prevalence of S. aureus underscores the
need for up-to-date and extensive insights regarding antimicrobial susceptibility trends. One
approach to meet this need is analysis of clinical laboratory – based surveillance data.
Methods: Data from The Surveillance Network-USA (TSN), an electronic surveillance network
that collects microbiology data from 300 clinical microbiology laboratories across the United
States, were used as the source for analysis that included prevalence of S. aureus in clinical
specimens, MRSA and multi-drug resistance phenotype rates and trends according to patient
location, geographic distributions, and specimen source.
Results: S. aureus was the most prevalent species isolated from inpatient specimens (18.7% of all
bacterial isolates) and the second most prevalent (14.7%) from outpatient specimens. In March
2005 MRSA rates were 59.2%, 55%, and 47.9% for strains from non-ICU inpatients, ICU, and
outpatients, respectively. This trend was noted in all nine US Bureau of Census regions and multi-
drug resistance phenotypes (resistance to ≥ 3 non-beta-lactams) was common among both
inpatient MRSA (59.9%) and outpatient MRSA (40.8%). Greater than 90% of multi-drug resistant
MRSA were susceptible to trimethoprim-sulfamethoxazole, linezolid, and vancomycin.
Conclusion: Prevalence of MRSA among both inpatient and outpatient specimens continues to
increase with multi-drug resistance as a common phenotype. Continued emergence of outpatient
MRSA that exhibit multi-drug resistant phenotypes has important implications for developing and
evolving outpatient treatment guidelines.
Background
Staphylococcus aureus exhibits three problematic features
that, taken together, are not found among most other clin-
ically relevant bacteria. This species is capable of express-
ing a variety of virulence factors and thus is almost always
considered medically relevant when encountered in clini-
cal specimens; the organism continues to demonstrate the
ability to develop and expand resistance to include a
broad array of antimicrobial classes, and S. aureus is a
prominent pathogen in both the hospital and the com-
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munity settings [1,2]. This combination of characteristics
underscores the need to monitor and report S. aureus
trends and patterns in a timely and thorough manner,
especially with regard to antimicrobial susceptibility pro-
files and the clinical settings in which the organism is
encountered.
To gain more extensive insights regarding recent antimi-
crobial trends among S. aureus, analysis of strain data
obtained from geographically and demographically
diverse patient populations in the United States is neces-
sary. One approach that can provide key information in
this regard involves the application of laboratory – based
surveillance. Analysis of microbiology data generated in
support of patient care by clinical laboratories across the
United States has been used in the past to provide perspec-
tive on a variety of antimicrobial resistance trends among
key bacterial pathogens [3-6]. Further, Fridkin et al [7]
have reported that laboratory derived antimicrobial data
can provide reliable perspectives on resistance rates
among patients with hospital – acquired infections.
Therefore, to help meet the need for current and broad-
based information regarding S. aureus trends, data
obtained through The Surveillance Network-USA (TSN)
were analyzed for resistance trends overall and in both the
inpatient and outpatient settings.
Methods
The Surveillance Network (TSN) was the data source used
for this investigation and analysis. TSN is an electronic
database of strain specific, qualitative and quantitative
antimicrobial susceptibility test data reported by clinical
laboratories in North America that has been used exten-
sively in the past to evaluate various trends regarding anti-
microbial susceptibility [3-6]. At the time of this analysis
TSN contained more than 105 million susceptibility test
results overall that were gathered from 300 USA hospitals
distributed across the United States. In addition to antimi-
crobial susceptibility profiles other query parameters that
may be used individually or in any combination for anal-
ysis of antimicrobial susceptibility data include organism
identification, national and regional geography (i.e. the
Relative frequency of bacterial species/groups encountered in clinical specimens from inpatients Figure 1
Relative frequency of bacterial species/groups encountered in clinical specimens from inpatients. Data is cumula-
tive data: 1998 – March 2005 and based on a total of 3,209,413 bacterial isolates.
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nine regions of the US Census Bureau), institution demo-
graphics (type, number of beds), patient demographics
(age, gender, and location), and specimen source.
This study focused specifically on S. aureus and used TSN
data collected from 1998 to March 2005. The overall prev-
alence of S. aureus isolated from inpatient and outpatient
specimens was calculated by using all organism groups
and species isolated from each patient group as the
denominator. MRSA rates for the study period were exam-
ined overall and according to three patient location cate-
gories as designated by each laboratory's information
system (outpatient, inpatient [non-ICU], and ICU). The
outpatient designation indicates that the specimen sub-
mitted for culture was obtained from patients seen in an
outpatient setting. For all patient locations three catego-
ries of clinical specimen source were analyzed and
included lower respiratory tract, skin and soft tissue
(included wounds), and blood. Multi-drug resistance for
MRSA was defined as resistance to three or more agents
among ciprofloxacin, erythromycin, clindamycin, gen-
tamicin, trimethoprim/sulfamethoxazole, linezolid, and
vancomycin. Only strains tested simultaneously against
all of these agents were included in the multi-drug resist-
ance analysis of prevalence and distribution of resistance
phenotypes.
Results
The top 20 most commonly reported bacterial species or
organism groups isolated from inpatient and outpatients,
as reported by clinical laboratories throughout the United
States from 1998 to 2005, are shown in Figures 1 and 2,
respectively. For both inpatient and outpatient specimens,
S. aureus and E. coli were the two most common species
reported. Among inpatients, S. aureus was more promi-
nent (18.7%) than E. coli (17.3%). For outpatient speci-
mens the reverse was noted; E. coli (38.6%) and S. aureus
(14.7%). The relative incidence of S. aureus among all
reported organisms was similar for inpatients (18.7%)
and outpatients (14.7%).
With regard to resistance trends, overall MRSA rates have
steadily increased in the USA since 1998 and the rate
appeared to be still on the rise as of March, 2005 (53.3%:
Relative frequency of bacterial species/groups encountered in clinical specimens from outpatients Figure 2
Relative frequency of bacterial species/groups encountered in clinical specimens from outpatients. Data is cumu-
lative data: 1998 – March 2005 and based on a total of 3,209,413 bacterial isolates.
0.4
0.4
0.5
0.6
0.6
0.7
0.8
0.9
0.9
1.0
1.0
1.0
1.5
4.2
6.2
6.3
6.5
8.8
14.9
38.6
0 5 10 15 20 25 30 35 40
% of all bacterial isolates encountered
Escherichia coli
Staphylococcus aureus
Enterococcus spp
Pseudomonas aeruginosa
Coagulase-negative staphylococci 
Klebsiella pneumoniae
Proteus mirabilis
Enterobacter cloacae
Streptococcus pneumoniae
Citrobacter freundii
Enterobacter aerogenes
Beta-hemolytic streptococci 
Serratia marcescens
Klebsiella oxytoca
Citrobacter koseri
Viridans group streptococci
Acinetobacter baumannii
Morganella morganii
Stenotrophomonas maltophilia
Haemophilus influenzaeAnnals of Clinical Microbiology and Antimicrobials 2006, 5:2 http://www.ann-clinmicrob.com/content/5/1/2
Page 4 of 9
(page number not for citation purposes)
Figure 3). An increase was noted among each patient
group including strains from ICU patients, non-ICU inpa-
tients, and outpatients with current MRSA rates of 55%,
59.2%, and 47.9%, respectively. Since 2002 the lowest
rate of increase in MRSA occurred among specimens from
ICU patients while the rates among S. aureus from other
inpatients and outpatients were higher.
Analysis of inpatient and outpatient MRSA rates according
to geographic distribution demonstrated that trends for
MRSA have occurred in each of the nine regions of the US
Census Bureau (Figure 4). In all regions, except New Eng-
land, inpatient MRSA rates were above 50%. The lowest
outpatient MRSA rates occurred in the Mid Atlantic
(36.3%) and New England (37.6%) regions; while the
highest rate (63%) occurred in the East South Central
region where inpatient and outpatient MRSA rates were
the same.
According to specimen source, MRSA rates were highest
(55.9%) among strains from inpatient lower respiratory
specimens and lowest (37.6%) among strains from outpa-
tient skin and soft tissue specimens (Table 1). For both
inpatients and outpatients the range of MRSA rates
according to specimen source was relatively narrow, 48.6
– 55.9% and 37.6 – 42.8%, respectively. Approximately
MRSA trends (1998 – YTD 2005) according to patient location Figure 3
MRSA trends (1998 – YTD 2005) according to patient location. Data is cumulative data: 1998 – March 2005. Red line, 
all patients; yellow line, ICU patients; green line, inpatients; blue line, outpatients.
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Table 1: MRSA rates among inpatients and outpatients by specimen sourcea
Inpatient Outpatient
Specimen Source Total N (%) MRSA Total N (%) MRSA
Lower Respiratory Tract 188,939 (55.9) 51,057 (42.8)
Skin and Soft Tissue 61,099 (48.6) 56,830 (37.6)
Blood 92,694 (49.1) 31,886 (41.4)
aCumulative data 1998 – March 2005Annals of Clinical Microbiology and Antimicrobials 2006, 5:2 http://www.ann-clinmicrob.com/content/5/1/2
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41% of S. aureus strains obtained from 31,886 blood cul-
tures taken in the outpatient setting were MRSA.
Regardless of the specimen source, the multi-drug resist-
ance rates among MRSA were higher among inpatient
strains than among outpatient strains (Table 2). For both
inpatient and outpatient MRSA, the highest multi-drug
resistance rates occurred among lower respiratory tract
isolates (67.8% for inpatients; 65% for outpatients) and
the lowest rates were among skin and soft tissue speci-
mens (35.8% for inpatients; 22.2% for outpatients).
For outpatient and inpatient MRSA combined, 29 differ-
ent resistance phenotypes were noted, 24 of which
occurred in both populations (Table 3). The spectrum of
phenotypes ranged from susceptibility to all non-beta-
lactams to resistance to five of the seven non-beta-lactams
included in the multi-drug resistance analysis. Resistance
to vancomycin was not encountered and non-susceptibil-
Inpatient (IP) and outpatient (OP) MRSA rates according to US Census Bureau Regions Figure 4
Inpatient (IP) and outpatient (OP) MRSA rates according to US Census Bureau Regions. Data is cumulative data: 
1998 – March 2005.
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Table 2: Multi-drug resistance (MDR)a rates among MRSA from inpatients and outpatients by specimen sourceb
Inpatient Outpatient
Specimen Source Total N (%) MDR Total N (%) MDR
Lower Respiratory Tract 5,134 (67.8) 1,136 (65.0)
Skin and Soft Tissue 2,122 (35.8) 2,275 (22.2)
Blood 3,064 (63.3) 904 (56.7)
aMultiple-drug resistance (MDR): resistance to three or more of the following agents: ciprofloxacin, erythromycin, clindamycin, gentamicin, 
trimethoprim/sulfamethoxazole, linezolid, and vancomycin
bCumulative data 1998 – March 2005Annals of Clinical Microbiology and Antimicrobials 2006, 5:2 http://www.ann-clinmicrob.com/content/5/1/2
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ity to linezolid occurred with three of 14,635 MRSA
strains (0.02%) profiled in this analysis. Susceptibility to
all non-beta-lactams studied was more common among
outpatient MRSA (5.7%) than among inpatient MRSA
(4.1%), but the frequencies of the susceptible phenotype
were comparable between MRSA strains from these two
patient populations.
The most common resistance phenotypes among inpa-
tient MRSA were multi-drug resistance to ciprofloxacin,
erythromycin, and clindamycin (47.6%), double drug
resistance to ciprofloxacin and erythromycin (18%), sin-
gle drug resistance to erythromycin (13.7%), and multi-
drug resistance to ciprofloxacin, erythromycin, clindamy-
cin, and gentamicin (8.3%) (Table 3). Among outpatient
MRSA single drug resistance to erythromycin (27.8%) was
the most common phenotype followed by multi-drug
resistance to ciprofloxacin, erythromycin, and clindamy-
cin (32.8%), and dual resistance to ciprofloxacin and
erythromycin (20.2%). In all, 11.4% (n = 1,179) of inpa-
tient MRSA were resistant to four or more non-beta-
lactam agents and 2.4% (n = 247) were resistant to five
agents. In comparison, 6.8% (n = 295) of outpatient
MRSA were resistant to four or more non-beta-lactams
and 1.5% (n = 63) were resistant to five agents.
For both outpatient and inpatient multi-drug resistant
MRSA the only agents with > 90% susceptibility were tri-
methoprim/sulfamethoxazole, linezolid, and vancomy-
cin (Table 4). This same hierarchy of antimicrobial
activity was maintained when data were analyzed accord-
ing to clinical specimen source (data not shown). The >
Table 3: Distribution of resistance phenotypesa among inpatient and outpatient MRSAb
Inpatient Outpatient
Category Resistance phenotype n (%) n (%)
Susceptible to all other agents - 418 (4.1) 245 (5.7)
Single-drug resistant Eryth 1409 (13.7) 1200 (27.8)
Cipro 232 (2.2) 92 (2.1)
Gent 8 (0.1) 3 (0.1)
Clinda 4 (0.0)c 5( 0 . 1 )
Double-drug resistant Cipro, Eryth 1854 (18.0) 870 (20.2)
Eryth, Clinda 114 (1.1) 104 (2.4)
Cipro, Clinda 62 (0.6) 23 (0.5)
Cipro, Gent 8 (0.1) 12 (0.3)
Cipro, SXT 14 (0.1) 2 (0.0)c
Eryth, SXT 2 (0.0)c 1( 0 . 0 ) c
Eryth, Gent 10 (0.1) 1 (0.0)c
Gent, SXT 2 (0.0)c 0( 0 . 0 )
Multidrug-resistant Cipro, Eryth, Clinda 4915 (47.6) 1417 (32.8)
Cipro, Eryth, Gent 30 (0.3) 18 (0.4)
Cipro, Eryth, SXT 23 (0.2) 7 (0.2)
Cipro, Gent, SXT 18 (0.2) 10 (0.2)
Eryth, Clinda, Gent 5 (0.0) 5 (0.1)
Cipro, Clinda, Gent 6 (0.1) 3 (0.1)
Eryth, Clinda, SXT 2 (0.0)c 1( 0 . 0 ) c
Eryth, Gent, SXT 0 (0.0) 1 (0.0)c
Cipro, Clinda, SXT 2 (0.0)c 0( 0 . 0 )
Cipro, Eryth, Lin 3 (0.0)c 0( 0 . 0 )
Cipro, Eryth, Clinda, Gent 858 (8.3) 214 (5.0)
Cipro, Eryth, Clinda, SXT 58 (0.6) 14 (0.3)
Cipro, Eryth, Gent, SXT 12 (0.1) 4 (0.1)
Eryth, Clinda, Gent, SXT 2 (0.0)c 0( 0 . 0 )
Cipro, Clinda, Gent, SXT 2 (0.0)c 0( 0 . 0 )
Cipro, Eryth, Clinda, Gent, SXT 247 (2.4) 63 (1.5)
Total n 10,320 4,315
aAnalysis included the following agents: gentamicin (Gent), erythromycin (Eryth), clindamycin (Clinda), trimethoprim-sulfamethoxazole (SXT), 
ciprofloxacin (Cipro), vancomycin (Vanc), and linezolid (Lin). Multi-drug resistance included resistance to three or more of the agents listed.
bCumulative data 2002 – March 2005
cn < 0.1% of totalAnnals of Clinical Microbiology and Antimicrobials 2006, 5:2 http://www.ann-clinmicrob.com/content/5/1/2
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99.9% linezolid susceptibility for inpatient MRSA strains
resulted from three of 6,183 strains being reported as non-
susceptible.
Discussion and conclusion
This analysis of data obtained through clinical laboratory
based surveillance has demonstrated that S. aureus contin-
ues to be solidly positioned as a leading bacterial patho-
gen encountered in both inpatient and outpatient clinical
settings and has continued to substantially outdistance
other gram-positive organisms in this regard. Because
most clinical microbiology protocols call for S. aureus to
be "worked-up" and reported regardless of the amount of
organisms present, or the type of specimen, there is a like-
lihood that the reporting frequency based on laboratory
data is higher than the actual frequency of infections
caused by this organism. Nonetheless, the same bias plays
a role for many other reported bacterial species so that the
position of S. aureus as the leading gram-positive organ-
ism, and its frequency relative to other species, is likely
quite reflective of actual infection rates as well. The high
prevalence of S. aureus reported here for both the inpa-
tient and outpatient environments was consistent with
recent descriptions and discussion regarding the changing
epidemiology of this organism [1,2].
The high prevalence of S. aureus in both settings under-
scores the need for analysis of antimicrobial resistance
trends according to patient location so that variations in
antimicrobial resistance trends among strains from
patients seen in the different clinical settings can be eval-
uated. Although previous surveillance initiatives that
included S. aureus have involved isolates from both out-
patients and inpatients, they examined strains collected
prior to 2002 and a thorough comparison of the resist-
ance rates and phenotypes according to patient location
were not reported [8,9]. In this current study antimicro-
bial data from geographically, demographically, and clin-
ically diverse settings, collected via The Surveillance
Network, were analyzed to provide a clearer and current
perspective on the resistance profiles currently present
among S. aureus in the United States.
The data provided in Figure 3 demonstrated that MRSA
rates continue to be on the rise among both inpatients
and outpatients, and this trend appeared to be pervasive
throughout all regions of the United States (Figure 4). Ris-
ing rates of MRSA in the hospital environment were
reported from studies done in previous years and data pre-
sented here indicate that the increasing rates have contin-
ued into 2005 [7,10-12]. The relatively lower increase in
MRSA observed here among ICU S. aureus is consistent
with the most recent report from the National Nosoco-
mial Infections Surveillance (NNIS) System Report [12].
Although the rate increase may be relatively lower than
before, the overall prevalence of MRSA in the ICU remains
high (55%).
In addition to the issue of increasing MRSA rates among
inpatients, the recognized emergence of MRSA beyond the
hospital or healthcare setting into the community has
raised another substantial public health concern about S.
aureus [2,13-17]. Based on this current laboratory – based
surveillance study the concern is much warranted as out-
patient MRSA rates have continued to increase to the
extent that as of 2005 the overall MRSA rate in this popu-
lation was 47.9% (Figure 3). Further, the data in Table 1
indicated that MRSA are commonly isolated from all types
of outpatient specimens, including blood.
MRSA that are encountered in the community (outpatient
settings) arise either as a result of acquisition of the mec
gene complex by susceptible S. aureus strains (so-called de
novo community MRSA), or by person-to-person carriage
of hospital strains into the community [2,18]. No pheno-
typic or genotypic criteria have been firmly established to
definitively specify a strain as being from one or the other
origin; this requires rigorous and diligent epidemiological
Table 4: Antibiograms of multi-drug resistanta MRSA from inpatients and outpatientsb
Inpatient (n = 6,183) Outpatient (n = 1,757)
Agents n (%) Susceptible n (%) Susceptible
Ciprofloxacin 7 (0.1) 5 (0.3)
Erythromycin 20 (0.3) 13 (0.7)
Clindamycin 85 (1.4) 38 (2.2)
Gentamicin 4,971 (80.4) 1,430 (81.4)
Trimethoprim-sulfamethoxazole 5,814 (94.0) 1,657 (94.3)
Linezolid 6,180 (>99.9) 1,757 (100)
Vancomycin 6,183 (100.0) 1,757 (100)
aMultiple-drug resistance: resistance to three or more of the following agents: ciprofloxacin, erythromycin, clindamycin, gentamicin, trimethoprim/
sulfamethoxazole, linezolid, and vancomycin
bCumulative data 1998 – 2005 YTDAnnals of Clinical Microbiology and Antimicrobials 2006, 5:2 http://www.ann-clinmicrob.com/content/5/1/2
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analysis. However, de novo MRSA have generally been
characterized as being susceptible to most non-beta-
lactam agents (other than erythromycin) while those that
have spread from the hospital setting into the community
often exhibit the multi-drug resistant phenotype that is
characteristic of most hospital-based strains [2,13,18,19].
The significant contrast in MRSA resistance phenotypes
that may exist depending on the origin of a community
strain (i.e. hospital or de novo) can confound empiric ther-
apeutic decisions when patients suspected of being
infected with S. aureus are initially evaluated in the outpa-
tient setting. While the rates of multi-drug resistant phe-
notypes among inpatient MRSA were higher than those
among outpatient MRSA, multi-drug resistance was a
common feature among the community outpatient popu-
lation (Table 2). In addition, there was substantial overlap
in phenotypes between inpatient and outpatient MRSA
(Table 3). These findings, based on data from across the
USA collected since 1998, indicate that strains of hospital
origin constitute the majority of MRSA encountered in the
outpatient setting. This is consistent with the local find-
ings reported by Charlebois et al. [18] in which a substan-
tial proportion of outpatient MRSA had resistance profiles
comparable to those of the hospital-based strains. Their
analysis led the authors to suggest that most of the com-
munity MRSA strains from the area studied around San
Francisco were likely descendants of hospital origin. Fur-
ther, a previous study we conducted also strongly sug-
gested that community MRSA frequently emerge from the
local hospital populations [4].
For multi-drug resistant inpatient and outpatient MRSA
alike there are relatively few agents that maintained high
levels of activity (Table 4). This situation combined with
the propensity of certain community clones to exhibit
substantial virulence with elaboration of toxins such as
Panton-Valentine Leuckocidin (PVL) raises concern about
future therapeutic guidelines for S. aureus infections
encountered in the outpatient settings [20-22].
The most common multi-drug resistant phenotype
encountered would preclude the use of all current beta-
lactams, clindamycin, macrolides, and fluoroquinolones
against outpatient MRSA. Although clindamycin is fre-
quently considered for infections in this setting, over 30%
of outpatient MRSA were resistant. The agents that con-
sistently demonstrated high levels of activity against out-
patient MRSA, including strains exhibiting the multi-drug
resistant phenotype, were trimethoprim/sulfamethoxa-
zole, linezolid, and vancomycin. No resistance to either
vancomycin or linezolid was encountered among outpa-
tient MRSA, including multi-drug resistant strains. There-
fore, while there have been reports of resistance to these
two agents, resistance remains sporadic and extremely rare
[1,23]. Because resistance to either vancomycin or line-
zolid is extremely rare among all S. aureus, use of either
agent is not likely to lead to expansion of multi-drug
resistant clones as could result from use of the other
agents to which S. aureus populations have already devel-
oped resistance. However, with regard to vancomycin, the
lack of an oral formulation with absorption introduces a
limitation as an option for the management of outpatient
MRSA infections. Linezolid has exhibited successful activ-
ity relative to vancomycin for MRSA and is available as an
oral formulation [24-26].
The continued increase in MRSA rates among inpatient
specimens coupled with the emergence of MRSA in the
community (outpatient) setting has involved strains that
frequently exhibit multiple drug resistance. For some time
these resistance phenotypes have been an issue for the
management of inpatients. Now current trends indicate
there are important implications for establishing outpa-
tient management and treatment guidelines for staphylo-
coccal infections. Given this trend, health care institutions
should consider analyzing their local S. aureus antibio-
grams according to outpatient and inpatient populations
in order to discern the prevalent phenotypes physicians
are likely to encounter in each setting. Finally, if the cur-
rent trend continues, the development of new anti-MRSA
agents for multi-drug resistant strains will have to con-
sider the need for both community and hospital use.
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